Drug Database
BE

betamethasone dipropionate (DFD01 / DFD 01 / Sernivo)

✓ Approved

Encore Dermatology, Inc. · 类固醇 · 类固醇

什么是 betamethasone dipropionate?

betamethasone dipropionate 是一种类固醇,由Encore Dermatology, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名DFD01, DFD 01, Sernivo
公司Encore Dermatology, Inc.
药物类别类固醇, 小分子
给药途径Topical
状态Approved

治疗适应症

betamethasone dipropionate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

相关研究文献

PubMedVestnik otorinolaringologii2026-11-18

[Possibilities of topical therapy of acute bullous otitis media].

Baranov K K KK, Vyazmenov E O EO, Kotova E N EN, Polunin M M MM et al.

Bullous myringitis is a borderline condition between inflammatory processes of the external and middle ear. The aim was to evaluate the comparative efficacy of three combined topical preparations in complex treatment of acute bullous otitis media. 140 patients aged 6-40 years (110 (78.6%) children) were divided into three groups: group 1 (n=50) - chloramphenicol+clotrimazole+beclomethasone dipropionate+lidocaine hydrochloride; group 2 (n=45) - phenazone+lidocaine; group 3 (n=45) - neomycin+polymyxin B+dexamethasone. Pain relief was fastest in group 2 (by day 3); otoscopic signs resolved by day 5, with the best combined results in group 1. In 25-28 (17.9-20.0%) patients bullous otitis was associated with PCR-confirmed influenza A (H1N1); Mycoplasma pneumoniae was detected in 4 (2.9%). The incidence peaked in December-February.

PMID 43046736
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Evaluation of Individualized Sequential Therapy Centered on Surgical Excision and Superficial Radiotherapy in Treating Keloids in the Anterior Chest Wall.

Zou Ming-Li ML, Shen Fang-Cheng FC, Wang Qian Q, Jiang Zi-Yu ZY et al.

This study aims to evaluate the efficacy of individualized sequential therapy centered on surgical excision and superficial radiotherapy for the treatment of sternal keloids. This study retrospectively analyzed the clinical data of 42 patients with sternal keloids admitted to a tertiary hospital in eastern China between January 2022 and December 2024. All patients received an individualized sequential therapy. Preoperatively, surgical approaches were selected based on the size and morphology of the keloids, including direct excision with tension-reduction sutures, flap reconstruction following excision, punch excision, and a combination of surgical excision and punch excision. Postoperative sequential adjuvant therapies included superficial radiotherapy, topical anti-scarring medications and dressings, and regular fractional laser treatment combined with compound betamethasone importation, sustained for 6 months. The Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) were used to evaluate scar improvement and clinical efficacy before treatment and at 12 months postoperatively. The response rate, recurrence rate, adverse reactions, and long-term outcomes were statistically analyzed. At 1 year postoperatively, VSS, OSAS, and PSAS scores decreased across all four subgroups compared with baseline. Significant differences between pre- and post-treatment scores were observed in the tension-reducing suture repair group (n = 18), IMAP flap reconstruction group (n = 9), and punch excision therapy group (n = 10) (all p < 0.05). The combined excision group (n = 5) showed a downward trend in postoperative scores, but the difference did not reach statistical significance (p = 0.063). The overall response rate was 88.1%. Postoperative radiation dermatitis occurred in 3 cases, which healed well after symptomatic management. During the follow-up period, recurrence was observed in 5 patients (11.9%), whose symptoms were alleviated following local injections of compound betamethasone. At the end of the follow-up period ranging from 12 to 24 months (mean: 19 months), all patients maintained stable or improved scar conditions, indicating favorable long-term efficacy. Individualized sequential therapy centered on surgical excision and superficial radiotherapy, combined with other long-term adjuvant treatments, demonstrates superior efficacy in the treatment of sternal keloids and is recommended for clinical application.

PMID 43047184
阅读全文 →
PubMedKidney international2026-11-18

Characterization of the Urine Proteome Using the Olink Explore 3072 Platform.

Meier Marisa M, Schoberth Mona M, Li Yong Y, Borisov Oleg O et al.

Urinary proteins are valuable biomarkers for physiological processes and early detection/monitoring of kidney diseases. However, comprehensive quantification and characterization of the urine proteome using a high-throughput platform remains limited. Using the affinity-based Olink Explore 3072 proteomics assay, we quantified 2868 proteins in urine samples from 1268 participants of the German Chronic Kidney Disease (GCKD) study. Protein detectability in urine, defined as the percentage of samples with measurements above the limit of detection, showed a bimodal distribution: 659 (23%) proteins had high (over 80%) and 1336 proteins (47%) had low (under 20%) detectability, with stable detectability across strata of albuminuria and kidney function. More than 95% of highly detectable proteins had previously been identified in urine by mass spectrometry. Highly detectable proteins were enriched for extracellular, exosomal, and cell surface localization, and for expression in hepatocytes, immune cells and kidney proximal tubule cells. Comparison with plasma detectability from the UK Biobank Pharma Proteomics Project identified proteins of likely kidney origin, including LRP2 (megalin) and NPHS2 (podocin). In a multivariable adjusted model of 13 clinical variables, albuminuria and an individual's sex showed significant associations with 779 and 670 proteins, respectively. Specific chronic kidney disease etiologies showed associations with 105 proteins, although etiology explained only a small proportion of protein variance. Correlation analysis revealed biologically meaningful protein clusters reflecting shared cellular compartments, tissue of origin, and molecular interactions. Large-scale urine proteomic profiling using a high-multiplex affinity-based platform captures biologically meaningful molecular variation associated with clinical variables and chronic kidney disease, providing a valuable resource for biomarker discovery and future targeted studies.

PMID 43051540
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

A Sequential Treatment of Keloids: Multiple-Hole Punch Excision Combined With Superficial Radiation and Drug.

Gong Zhicheng Z, Jing Wenwen W, Zhang Zhenhua Z, Rao Wenbin W et al.

Dense and multiple keloids present significant therapeutic challenges due to their stubborn nature and high recurrence rates. Although various treatment options exist, optimizing current approaches and integrating them into a rational, systematic regimen for keloid management remains a difficult clinical problem. This study aims to establish an effective multimodal sequential treatment protocol for patients with dense, multiple keloids. A total of 87 patients with 285 keloid lesions were enrolled from September 2023 to April 2024. All cases underwent a sequential treatment: Stage I involved drug-assisted multiple-hole punch excision followed by adjuvant superficial radiotherapy; Stage II consisted of periodic intralesional injections of betamethasone and 5-fluorouracil. Clinical outcomes, recurrence, and adverse events were evaluated at 12-month follow-up. The POSAS and VSS scores were recorded at each time point. At 12 months post-treatment, marked improvement was achieved in 78 patients (89.66%), with improvement in 7 (8.04%) and ineffective results in 2 (2.30%). The POSAS and VSS scores were recorded before treatment and at follow-up points at 30, 60, 90, 180, and 360 days. All patients developed varying degrees of local hyperpigmentation within 2 months after Stage I of multi-hole punch excision. In 80.75% of cases, the hyperpigmentation resolved within 3 months following Stage I, with the longest duration of resolution being 12 months. During Stage I, four cases of localized ulcers and five instances of acute radiation dermatitis appeared. All adverse reactions were effectively alleviated. No other adverse reactions occurred. This sequential treatment protocol offers a practical, minimally invasive, and effective option for patients with multiple, dense keloids.

PMID 43047096
阅读全文 →
PubMedCureus2026-11-16

Immediate Implant Placement With Peri-Implant Contour Augmentation in the Maxillary Central Incisor: A Three-Year Clinical and Cone-Beam Computed Tomography Follow-Up.

Tanuja B B, Ramesh A A, Kotha Haritha H, Pavani Y Y et al.

Although immediate implant placement in the anterior maxilla can shorten the treatment timeline, it presents challenges in preserving peri-implant hard- and soft-tissue contours. We report the three-year clinical and radiographic outcome of immediate implant placement combined with peri-implant contour augmentation in the region of the maxillary right central incisor. A 20-year-old man presented two months after trauma with a non-restorable cervical fracture of the maxillary right central incisor. Clinical and cone-beam computed tomography (CBCT) evaluation demonstrated facial bone deficiency with sufficient apical and palatal bone for immediate implant placement. Following atraumatic extraction, a 4 × 14 mm implant was placed in a prosthetically driven three-dimensional position with primary stability of 35 Ncm. The peri-implant gap and facial contour were augmented using deproteinized bovine bone mineral (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and a resorbable collagen membrane. Following uneventful healing, second-stage surgery was performed at three months, followed by definitive ceramic crown placement. At the three-year follow-up, the implant remained clinically stable, with healthy peri-implant soft tissues and preserved facial contour, without signs of inflammation, infection, or mobility. CBCT demonstrated maintained bone in the crestal and mid-buccal regions, with satisfactory osseointegration and preservation of peri-implant hard-tissue support. Careful case selection, atraumatic extraction, prosthetically driven implant positioning, primary stability, and appropriate management of facial bone deficiencies are important considerations for achieving predictable outcomes.

PMID 43036423
阅读全文 →
PubMedFrontiers in artificial intelligence2026-11-15

Navigating the Pharma 4.0 revolution: how AI-enabled applications and predictive modelling shaped pharmaceutical development in the post-pandemic era: a systematic review.

Chang Xin Yi XY, Teo Clarence C, Goh Cheong Hian CH

Pharma 4.0 is touted to make processes more efficient and resilient to unforeseen circumstances, boosting productivity, speed and accuracy of pharmaceutical systems. Besides operational stability, these technological implementations could potentially improve clinical outcomes. AI-enabled Pharma 4.0 applications and predictive modelling are utilised in pharmaceutical development for the discovery of new compounds that could potentially be used as drugs for COVID-19. This systematic review examined how contemporary Pharma 4.0 technologies have impacted pharmaceutical development in the post COVID-19 pandemic. A systematic review following the "Preferred Reporting Items for Systematic Review and Meta-Analyses" (PRISMA) method was carried out on scientific peer-reviewed literature, covering the period from 2023 to 2025. From the PubMed and Scopus databases, 593 articles were identified and 57 were included for further analysis. Performance metrics describing the reported predictive models used in research areas were identified and descriptive statistics were used to present the findings. We found that predictive models of Pharma 4.0 technologies were predominantly concentrated in early-stage drug discovery and computational research, with reported benefits of more efficient and accurate processes. Our current findings on the nonclinical performance metrics observed good use cases for drug discovery, but limited insights on the clinical applications that these recent technological developments had on the pharmacological effects. These technologies enhanced complex processes, facilitated predictive models to optimise product development in the early phase of the product life cycle.

PMID 43032471
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多betamethasone dipropionate